Supreme court in Amgen v. Sanofi Opinion patent genus claims, due care should be taken to enable the full breadth of the claims large genus is encompassed by the claims and enablement may be a concern, practitioners should consider multiple claiming strategies
In May, the Supreme Court of the United States handed down its decision in Amgen Inc. v. Sanofi, which addressed the statutory enablement requirement for patents. The decision is.
For nearly a decade, Amgen Inc. and Sanofi had been embroiled in a patent infringement dispute over Amgen patents covering broad classes of antibodies beneficial to human blood.
On May 18, 2023, the Supreme Court affirmed the Federal Circuit’s (CAFC) decision on enablement in Amgen Inc. v. Sanofi, 987 F.3d 1080 (CA Fed. 2021). The Court thus left in place a.
While patented technology and U.S. patent laws are often complex, the foundation of our patent system is based on a fairly simple quid pro quo. In exchange for publicly disclosing information that advances.